Life Sciences Tools and Services(IN20268.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Life Sciences Tools and Services
IN20268.HK
News
View More

Frontage Holdings Opens Fully Operational GMP Facility with Advanced Manufacturing Capabilities

Frontage Holdings Corporation has launched a new GMP facility, operational since October 2025, enhancing its pharmaceutical development and manufacturing capabilities. The facility includes advanced equipment for aseptic filling, tablet pressing, and more, supporting clinical and small-scale commercial production of various dosage forms. This expansion aims to provide efficient manufacturing solutions for small and mid-sized pharmaceutical companies.

Reuters·
HK
01521
-0.96%
Reuters·
HK
01521
-0.96%

JPM26: Bi- and multispecific modalities power Wuxi Biologics growth

Wuxi Biologics showcased its integrated platform for biologics at the JP Morgan Healthcare Conference, emphasizing its end-to-end capabilities in research, development, and manufacturing. CEO Chris Chen highlighted their success with over 600 INDs and a 100% regulatory inspection success rate. The company focuses on bi- and multispecifics, ADCs, and mAbs, which contribute 20% of revenue. Wuxi is expanding its manufacturing capacity in the US and Asia, including a new facility in Qatar. Chen noted the adoption of AI technologies to enhance operations, predicting significant revenue growth in 2026 and beyond.

Pharmaceutical Technology·
US
WXXWY
-0.69%
HK
02269
+0.05%
Pharmaceutical Technology·
US
WXXWY
-0.69%
HK
02269
+0.05%

Top 10 HK Stock Losers (1.15)

TRIP.COM-S(09961) fell 19.23%, with a trading turnover 15.8 Billion HKD, and a year-to-date fell 17%. AFFLUENT FDN(01757) fell 17.15%, with a trading turnover 42.9 Million HKD, and a year-to-date rose 87.3%. IVD MEDICAL(01931) fell 12.8%, with a trading turnover 19.9 Million HKD, and a year-to-date fell 16.8%.

Top Gainers & Losers·
HK
09961
-19.23%
HK
01757
-17.15%
HK
01931
-12.80%
Top Gainers & Losers·
HK
09961
-19.23%
HK
01757
-17.15%
HK
01931
-12.80%

WuXi Biologics CEO reports 945 integrated projects by 2025, including 74 Phase III and 25 commercial manufacturing.209 new projects in 2025, with 50% from U.S. clients.

In 2025, there were a total of 945 integrated projects, with 74 being in Phase III clinical development and 25 focused on commercial manufacturing. A record-breaking 209 new integrated projects were initiated in the same year, with around half of them stemming from clients based in the United States. Complex modalities form the primary growth driver for WuXi Biologics.

Unusual Whales·
US
WXXWY
-0.69%
HK
02269
+0.05%
Unusual Whales·
US
WXXWY
-0.69%
HK
02269
+0.05%

23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

Dr. Chris Chen, CEO of WuXi Biologics, presented at the J.P. Morgan Healthcare Conference, highlighting the company's growth and achievements for 2025. WuXi Biologics plans to complete 945 integrated projects, with a significant focus on bispecific/multispecific antibodies and ADCs, which are driving revenue growth. The company has secured record-breaking deals and is expanding its global manufacturing capabilities. WuXi Biologics aims to enhance its CRDMO model to support biopharmaceutical innovators, showcasing strong client trust and a robust project pipeline.

prnewswire·
US
WXXWY
-0.69%
HK
02269
+0.05%
prnewswire·
US
WXXWY
-0.69%
HK
02269
+0.05%
Posts
View More

$XTALPI(02228.HK) was dumbfounded 😁

$XTALPI(02228.HK) Close a position first. Stay patient. The general direction remains unchanged. This should be a reasonable adjustment that @Zhou Shuren's trader buddy is waiting for.

  • 0

$XTALPI(02228.HK) Can't help it. Just give it a try.

  • 0

$XTALPI(02228.HK) MM's determination is very firm! Hold steady, small positions can pick up money, but don't lose the watermelon.

  • 0

$XTALPI(02228.HK) It's just inertia, hold steady, hold steady. Don't move the main force. Bought back 50,000 short positions

  • 0
© 2026 Longbridge｜Disclaimer